Heron Therapeutics News and Activities
Presence
Heron Therapeutics develops and sells biotechnology medicines for pain management and supportive care. Its products help hospitals, clinics, and healthcare professionals treat surgery patients and people receiving cancer-related care.
Heron Therapeutics products and services overview:
- Pain management
- Supportive care
- Postoperative medicines
- Cancer care therapies
Revenue: ~$149 million
Employees: 310
Headquarters: San Diego, United States (USA)
Heron Therapeutics is one of the...
Heron Therapeutics is a company listed under the stock ticker HRTX (US).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Heron Therapeutics
- Craig Collard, Director and Chief Executive Officer
- Susan Rodriguez, Director
- Christian Waage, Director
Popular executive movements at Heron Therapeutics
- Thomas Cusack has joined the company as Director (posted on October 30 2025).
Create your alert
to follow the executive moves at Heron Therapeutics.
Biotechnology
Heron Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Heron Therapeutics
- Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 - Heron Therapeutics
- Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability - Heron Therapeutics
- News Releases - Heron Therapeutics
- News Releases - Heron Therapeutics
- Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty - Heron Therapeutics
- Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference - Heron Therapeutics
- Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting - Heron Therapeutics
- Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates - Heron Therapeutics
- Heron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022 - Heron Therapeutics
- Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative Pain | Heron Therapeutics
- View more press releases Close
Social media about Heron Therapeutics
- Heron Therapeutics on Wikipedia, Google News & Yahoo Finance
- Heron Therapeutics on LinkedIn, X (Twitter) & YouTube
